20-068 - Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
Status: openA Multicenter, Longitudinal, Open-label, Single-arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod
Patients with Relapsing Multiple Sclerosis
Description
This is a phase 3 clinical trial with ozanimod in relapsing forms of multiple sclerosis. The primary objective is to determine if and how cognition changes when taking ozanimod. This is a 3 year study with approximately 4 visits per year.
Sponsors
This trial is sponsored by Celgene.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Sub Investigators
This link will open in a new tab or window.